Stimulation for Perinatal Stroke Optimizing Recovery Trajectories
(SPORT Trial)
Trial Summary
What is the purpose of this trial?
Perinatal stroke causes lifelong neurological disability and most hemiparetic cerebral palsy (CP). With morbidity spanning diverse aspects of a child's life and lasting for decades, global impact is large, including 10000 Canadian children. With pathophysiology poorly understood and prevention strategies non-existent, the burden of hemiparetic CP will persist. Limited treatments lead to loss of hope for children and families, necessitating exploration of new therapies. The investigators have evidence that the investigators have a durable new treatment for perinatal stroke, combining non-invasive neurostimulation and child-centred intensive rehabilitation. Via the CHILD-BRIGHT SPOR national network, the investigators will execute a multicentre trial to prove this treatment can improve function in children with perinatal stroke and hemiparetic CP. Using novel advanced technologies not available elsewhere in the world, the investigators will explore how developmental plasticity determines function and response to neuromodulation therapy. This patient oriented effort will advance personalized, precision medicine in pediatric neurorehabilitation to improve outcomes for disabled children and their families.
Research Team
Adam Kirton, MD
Principal Investigator
University of Calgary
Eligibility Criteria
Inclusion Criteria
Treatment Details
Interventions
- Cathodal transcranial direct current stimulation (Neuromodulation Therapy)
- Sham transcranial direct current stimulation (Neuromodulation Therapy)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Calgary
Lead Sponsor
Dr. Shweta Patel
University of Calgary
Chief Medical Officer since 2020
MD from the University of Baroda Medical College, India
Dr. Edward McCauley
University of Calgary
President and Vice-Chancellor since 2018
PhD in Ecology and Evolutionary Biology from the University of California, Santa Barbara
University of Alberta
Collaborator
Bill Flanagan
University of Alberta
Chief Executive Officer since 2020
LLB from University of Toronto, LLM from Columbia University
Dr. Verna Yiu
University of Alberta
Chief Medical Officer since 2012
MD from University of Alberta, Fellowship in Pediatric Nephrology at Harvard University
Holland Bloorview Kids Rehabilitation Hospital
Collaborator
Julia Hanigsberg
Holland Bloorview Kids Rehabilitation Hospital
Chief Executive Officer since 2015
Law degrees from McGill University and Columbia Law School
Dr. Golda Milo-Manson
Holland Bloorview Kids Rehabilitation Hospital
Chief Medical Officer since 2010
MD from University of Toronto
The Hospital for Sick Children
Collaborator
Dr. Ronald D. Cohn
The Hospital for Sick Children
Chief Executive Officer since 2019
MD from University of Düsseldorf, Germany
Dr. Lennox Huang
The Hospital for Sick Children
Chief Medical Officer since 2016
MD from McGill University